NCT06457230 Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder
| NCT ID | NCT06457230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Mental Health Center |
| Condition | Methamphetamine Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-12-24 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-12-24 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the mechanism and efficacy of a novel repetitive transcranial magnetic stimulation (rTMS) intervention model with paired cerebellar-medial prefrontal cortex (mPFC) pulses on methamphetamine use disorder patients and to develop a novel physiotherapeutic intervention to optimise the treatment and management.
Eligibility Criteria
Inclusion Criteria Participants will be eligible for inclusion if they meet the following criteria: 1. Methamphetamine is the primary substance of use, and the participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for moderate or severe methamphetamine use disorder; 2. aged 18 to 60 years; 3. normal or corrected-to-normal vision and hearing, and right-handedness; 4. primary school education or above, with the ability to understand the questionnaires and behavioral task instructions. Exclusion Criteria Participants will be excluded if they meet any of the following criteria: 1. presence of metal objects in the body, such as metal dentures, orthodontic braces, bone fixation plates, aneurysm clips, or other metallic implants; 2. severe physical illness or chronic disease, including heart disease, severe hypertension, stroke, epilepsy, or history of head trauma; 3. comorbid psychiatric disorders, such as bipolar disorder, schizophrenia, or severe depression; 4. previous participation in transcranial magnetic stimulation- or electroencephalography-related studies; 5. refusal to participate in the study, poor compliance, or any other contraindications to transcranial magnetic stimulation.
Contact & Investigator
Min Zhao, PhD
STUDY CHAIR
Shanghai Mental Health Center
Frequently Asked Questions
Who can join the NCT06457230 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 60 Years, studying Methamphetamine Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06457230 currently recruiting?
Yes, NCT06457230 is actively recruiting participants. Contact the research team at drminzhao@gmail.com for enrollment information.
Where is the NCT06457230 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06457230 clinical trial?
NCT06457230 is sponsored by Shanghai Mental Health Center. The principal investigator is Min Zhao, PhD at Shanghai Mental Health Center. The trial plans to enroll 90 participants.